35961-41-2

Basic information

• Product Name: 3-(tetrahydro-2H-pyran-2-yloxy)pregn-5-en-20-one
• CAS NO: 35961-41-2
• Molecular Formula: C₂₆H₄₀O₃
• Molecular Weight: 400.594
• Mol File: 35961-41-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 508.9°C at 760 mmHg
• Flash Point: 254°C
• Density: 1.09g/cm³
• Vapor Pressure: 1.78E-10mmHg at 25°C
• Refractive Index: 1.54
• CAS DataBase Reference: 3-(tetrahydro-2H-pyran-2-yloxy)pregn-5-en-20-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(tetrahydro-2H-pyran-2-yloxy)pregn-5-en-20-one(35961-41-2)
• EPA Substance Registry System: 3-(tetrahydro-2H-pyran-2-yloxy)pregn-5-en-20-one(35961-41-2)

Safety Data

• Hazardous Substances Data: 35961-41-2(Hazardous Substances Data)

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 145-13-1 Pregnenolone 
• 979-02-2 16-dehydropregnenolone acetate 
• 1778-02-5 Pregnenolone acetate 

Downstream Products

• 41083-90-3 cholesta-5,20-diene-3β-ol 
• 13095-61-9 (25R)-cholest-5-ene-3β,26-diol 
• 85707-11-5 Toluene-4-sulfonic acid (R)-1-[(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethyl ester 
• 88904-71-6 (3E,5E)-2-[(3S,8S,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-(4-methoxy-phenyl)-5-phenylsulfanyl-hexa-3,5-dien-2-ol 
• 84056-77-9 (E)-2-[(3S,8S,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-ethyl-5-phenylsulfanyl-octa-3,5-dien-2-ol 
• 84051-51-4 (E)-2-[(3S,8S,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-phenylsulfanyl-hepta-3,5-dien-2-ol 
• 84051-55-8 (3Z,5E)-6-[(3S,8S,9S,10R,13S,14S,17R)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-3-phenylsulfanyl-hepta-3,5-dien-2-ol 
• 84056-77-9 (E)-(S)-2-[(3S,8S,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-ethyl-5-phenylsulfanyl-octa-3,5-dien-2-ol 
• 84051-51-4 (E)-(S)-2-[(3S,8S,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-phenylsulfanyl-hepta-3,5-dien-2-ol 
• 84051-55-8 (3Z,5E)-6-[(3S,8S,9S,10R,13S,14S,17R)-10,13-Dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-3-phenylsulfanyl-hepta-3,5-dien-2-ol 
• 118143-31-0 2-Iodo-benzoic acid (R)-1-[(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethyl ester 
• 118143-30-9 2-Iodo-benzoic acid (S)-1-[(3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethyl ester 
• 118143-35-4 pregn-5-ene-3β,20β-diol 20-(2-iodobenzoate) 
• 118143-33-2 pregn-5-ene-3β,20α-diol 20-(2-iodobenzoate) 

Relevant articles and documents

High-field NMR studies of 3β-tetrahydropyranyloxy steroids

Comprehensive NMR studies were carried out on 3β-hydroxy-pregnene and cholestene analogs, each containing a tetrahydropyranyl ether group at the 3-position. Two-dimensional NMR experiments (COSY, TOCSY, HSQC, and HSQC-TOCSY) permitted the complete assignments of both the 1H and 13C resonances of these derivatives in deuterated benzene or chloroform. The aromatic solvent-induced NMR signal shifts (ASIS) were also investigated. Copyright (C) 2000 Elsevier Science Inc.

Synthesis of potential pregnenolone and progesterone spin probes for biomembranes and immunoassays

The synthesis and characterization of four new steroidal spin labels, viz., 3'-[[(pregn-5-en-3β-ol-20S-yl)methyl]oate]-2',2',5',5'- tetramethylpyrrolidine-1'-oxyl,3'-[[(pregn-4-en-3-one-20S-yl)methyl]oate]- 2',2',5',5'-tetra methyl pyrrolidine-1'-oxyl, 3'-[(3β-acetoxypregn-5-en-20- one-16α-yl)prop-2'ξ-ol-3'ξ-oate]-2',2',5',5'-tetramethyl pyrrolidine-1- oxyl and 3-[(pregn-5-en-3,20-dione-16α-yl)prop-2'ξ-ol-3'ξ-oate]- 2',2',5',5'-tetramethylpyrrolidine-1'-oxyl has been described which involves functionalization of the parent hormone at C-20 and C-16. The key step to all the products was the condensation of 3-carboxyproxyl with the derivatized synthons.

New crystalline form of vascular leak blocker compound

The present invention relates to a crystalline form of (E)-methyl 6-((3S,8S,9S,10R,13S,14S,17R)-3-(((5S,6R)-5-acetoxy-6-(acetoxymethyl)-5,6-dihydro-2H-pyran-2-yl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)hept-5-enoate and a vascular leakage blocker comprising same. The novel crystalline form has high purity and excellent stability with consequent excellent long-term storage and pharmaceutical stability, and is available for use as a vascular leakage blocker, and as such, is very advantageous in producing high-quality drug substances.

20-triazole-20-hydroxyl-pregnane derivatives, method for preparing same and medical application of 20-triazole-20-hydroxyl-pregnane derivatives

The invention belongs to the field of medicines, and particularly relates to a series of 20-triazole-20-hydroxyl-pregnane derivatives, a method for preparing the same and medical application of the 20-triazole-20-hydroxyl-pregnane derivatives. The 20-triazole-20-hydroxyl-pregnane derivatives are particularly used for preparing medicines for treating androgen receptor related diseases such as cellproliferation, prostate cancer, polytrichia, acne and androgenic alopecia which are dependent on androgens. Structural general formulas of compounds of the 20-triazole-20-hydroxyl-pregnane derivativesare shown. Details of definition of various groups in the general formulas are attached to specifications.